MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Search

Bio-Techne Corp

Suletud

SektorTervishoid

65.27 3.55

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

62.47

Max

66.09

Põhinäitajad

By Trading Economics

Sissetulek

56M

38M

Müük

-30M

287M

P/E

Sektori keskmine

121.212

87.826

Dividenditootlus

0.54

Kasumimarginaal

13.326

Töötajad

3,100

EBITDA

71M

78M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+10.88% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.54%

2.26%

Järgmine tulemuste avaldamine

4. veebr 2026

Järgmine aktsia dividendi kuupäev (ex-date)

13. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

283M

9.8B

Eelmine avamishind

61.72

Eelmine sulgemishind

65.27

Uudiste sentiment

By Acuity

41%

59%

139 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Bio-Techne Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. nov 2025, 22:36 UTC

Tulu

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Bio-Techne Corp Prognoos

Hinnasiht

By TipRanks

10.88% tõus

12 kuu keskmine prognoos

Keskmine 66.14 USD  10.88%

Kõrge 72 USD

Madal 60 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Bio-Techne Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

6

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

49.67 / 50.24Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

139 / 374 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat